Q-omics provides the consensus-scored SNORA79B profile across patient tissues and cancer cell-line models. SNORA79B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNORA79B is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SNORA79B RNA expression shows 15,157 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where SNORA79B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA79B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA79B survival associations across molecular data types. SNORA79B RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA79B RNA expression–survival associations across cancer types. High SNORA79B expression shows unfavorable associations in UCEC, UVM and BLCA, but favorable associations in UCS, ESCA and READ. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SNORA79B RNA expression.
This table summarizes SNORA79B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA79B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA79B shows lower tumor expression in KIRC and THCA and higher tumor expression in STAD, COAD, LUAD and LIHC. The KIRC box plot shows higher SNORA79B RNA expression in normal versus tumor tissue (log2 FC = −0.320, t-test p = .005).
This table shows molecular features associated with SNORA79B in patient tissues and cancer cell lines. In patient samples, SNORA79B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
